Seres Therapeutics (NASDAQ:MCRB) Share Price Passes Above Fifty Day Moving Average of $0.83

Seres Therapeutics, Inc. (NASDAQ:MCRB)’s stock price crossed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $0.83 and traded as high as $0.93. Seres Therapeutics shares last traded at $0.92, with a volume of 1,483,083 shares.

Analyst Ratings Changes

MCRB has been the subject of a number of recent analyst reports. Oppenheimer cut their price objective on Seres Therapeutics from $5.00 to $4.00 and set an “outperform” rating for the company in a research report on Thursday, May 9th. Chardan Capital lowered their target price on Seres Therapeutics from $8.00 to $6.00 and set a “buy” rating for the company in a report on Wednesday, May 8th.

Seres Therapeutics Trading Up 1.0 %

The business has a fifty day moving average of $0.83 and a 200 day moving average of $1.03.

Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings data on Tuesday, March 5th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.08. The company had revenue of $0.06 million during the quarter, compared to analysts’ expectations of $0.50 million. As a group, equities analysts anticipate that Seres Therapeutics, Inc. will post -1.02 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Seres Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC purchased a new position in shares of Seres Therapeutics in the 4th quarter valued at about $73,000. Hudson Bay Capital Management LP boosted its stake in shares of Seres Therapeutics by 127.3% in the 3rd quarter. Hudson Bay Capital Management LP now owns 1,999,800 shares of the biotechnology company’s stock valued at $4,760,000 after buying an additional 1,119,800 shares during the period. Aigen Investment Management LP lifted its stake in Seres Therapeutics by 577.1% during the third quarter. Aigen Investment Management LP now owns 75,241 shares of the biotechnology company’s stock worth $179,000 after purchasing an additional 64,128 shares during the last quarter. Graham Capital Management L.P. lifted its stake in Seres Therapeutics by 731.3% during the third quarter. Graham Capital Management L.P. now owns 206,838 shares of the biotechnology company’s stock worth $492,000 after purchasing an additional 181,957 shares during the last quarter. Finally, Handelsbanken Fonder AB lifted its stake in Seres Therapeutics by 10.0% during the fourth quarter. Handelsbanken Fonder AB now owns 1,100,000 shares of the biotechnology company’s stock worth $1,540,000 after purchasing an additional 100,000 shares during the last quarter. Hedge funds and other institutional investors own 59.34% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.